| Trial ID: | L6885 |
| Source ID: | NCT01324505
|
| Associated Drug: |
Semaglutide
|
| Title: |
Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: semaglutide|DRUG: placebo|DRUG: Microgyn®
|
| Outcome Measures: |
Primary: Area under the ethinylestradiol concentration-time curve, in the 24 hour dosing interval|Area under the levonorgestrel concentration-time curve, in the 24 hour dosing interval | Secondary: Maximum oral contraceptive concentration, in the 24 hour dosing interval|Area under the semaglutide concentration-time curve, in the 24 hour dosing interval|Maximum semaglutide concentration, within the weekly dosing interval|Percentage of subjects experiencing adverse events, from week 1 to end of trial at maximum 23 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
FEMALE
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
43
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-03
|
| Completion Date: |
2012-01
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-08
|
| Locations: |
Novo Nordisk Investigational Site, Neuss, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01324505
|
